ideology-health
  • Our Solutions
  • About Us
    • ideology-health
    Privacy Policy
    Terms of Service

    IDEOlogy Health Ranks No. 772 on the 2025 Inc. 5000 Fastest-Growing Private Companies in America

    © 2025 IDEOlogy Health. All product names, logos, brands, trademarks and registered trademarks are property of their respective owners and their use(s) do not necessarily imply endorsement.

    G

    Dr Gregory Vidal,

    Medical professional dedicated to sharing knowledge and insights through educational videos.

    Dr. Gregory Vidal discusses safety, tolerability, and NCCN categorization of margetuximab-cmkb in HER2+ mBC (Video 3/3)

    Dr. Gregory Vidal discusses safety, tolerability, and NCCN categorization of margetuximab-cmkb in HER2+ mBC (Video 3/3)

    SOPHIA- Safety

    Gregory Vidal
    ASCO Updates
    Breast Cancer
    +1 more
    Dr. Gregory Vidal discusses the key efficacy outcomes of margetuximab-cmkb in HER2+ mBC (Video 2/3)

    Dr. Gregory Vidal discusses the key efficacy outcomes of margetuximab-cmkb in HER2+ mBC (Video 2/3)

    SOPHIA- Study design, efficacy

    Gregory Vidal
    ASCO Updates
    Breast Cancer
    +1 more
    Dr. Gregory Vidal discusses the unique MOA of margetuximab-cmkb and combinability in HER2+ mBC (Video 1/3)

    Dr. Gregory Vidal discusses the unique MOA of margetuximab-cmkb and combinability in HER2+ mBC (Video 1/3)

    SOPHIA-MOA

    Gregory Vidal
    ASCO Updates
    Breast Cancer
    +1 more